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Abstract
Background: Erectile dysfunction is a common problem in type 2 diabetic patients who are at higher risk of
cerebrovascular events, and it’s recorded with sildenafil, a drug which is primarily used for erectile dysfunction.
Objectives: We tested the hypothesis whether or not sildenafil modulates cerebrovascular reactivity (CVR) in
patients with type 2 diabetes mellitus.
Methods: A total of 35 male participants were enrolled; eighteen with type 2 diabetes mellitus matched with
seventeen normal individuals. Transcranial Doppler Ultrasonographic examination (TCD) was performed for all
participants to insonate the middle cerebral artery (MCA) through a trans-temporal window. CVR was assessed by
using breath holding (BH)-hyperventilation (HV) test, before and after oral 50 mg sildenafil; recordings were
analyzed by using SPSS program version 12.
Results: In normal individuals, sildenafil did not result in statistically significant change in breath holding index
(BHI) from 0.91 ± 0.11 to 0.81 ± 0.09 and full range of vasodilatation (FVD) from (59.4% ± 6.3%) to (53.7% ± 4.9%).
In diabetic patients, giving sildenafil resulted in significant increase in BHI (from 0.74 ± 0.14 to 1.03 ± 0.14) and FVD
(from 60.2% ± 4.96% to 74% ± 4.8%), (p < 0.05).
Conclusion: Sildenafil significantly improves CVR in type 2 diabetic patients but not in normal subjects.
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Introduction
Cerebrovascular reactivity (CVR) may be defined as the
capability of intracerebral arterioles to constrict and to
dilate ensuring constant cerebral blood flow despite
changes in systemic blood pressure [1]. There are two
types of cerebrovascular reactivity; first, mechanical cer-
ebro-vascular reactivity which does not depend on nitric
oxide (NO), second, chemical cerebrovascular reactivity
which is endothelial in origin and NO dependent [2].
Carbon dioxide is a potent cerebral vasodilator, there-
fore, hypercapnea induces cerebral vasodilatation and
hypercapnea or hyperoxia induces cerebral vasoconstric-
tion [3,4]. CO2- N Oa x i si sac a r d i n a lp a t h w a yi nt h e
chemoregulation of cerebral blood flow (CBF) in
humans; additionally, the results of Lavi et al, supported
the hypothesis that endothelial dysfunction would result
in impaired CO2 vasoreactivity (chemoregulation) of
cerebral vasculature. This chemical cerebrovascular
reactivity was described by Markus and Harrison who
used breath holding/hyperventilation test for assessment
of cerebrovascular reactivity. They measured the breath
holding index (BHI) and full range of vasodilatation
(FVD) of middle cerebral artery using transcranial Dop-
pler; it has been shown that Breath holding is effective
in inducing cerebral vasodilatation while hyperventila-
tion is effective in inducing cerebral vasoconstriction.
It has also been demonstrated that endothelial func-
tion is more altered in type 2 diabetic patients than in
type 1 diabetic patients, regardless of the differences in
their blood glucose control levels [5], suggesting a possi-
bility of involvements of other factors; a longer period
of undetected blood glucose abnormalities, lipid altera-
tions or decreased insulin sensitivity could be involved.
Therefore, the initial acethylcholine-endothelium depen-
dent dysfunction can be improved by the normalization
of blood glucose control in type 1 diabetes mellitus,
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mellitus, Further, it has been reported that diabetes
alters endothelial function and permeability of the
blood-brain barrier, thus affecting micro-circulation and
regional metabolism [5] with the result of impaired CVR
(less increase in CBF).
I nr e l e v a n c et ot h ec u r r e n ts t u d y ,i ti se s s e n t i a lt o
shed some light on literature reports focusing on silde-
nafil and Cerebral Vasoreactivity: Sildenafil is known
to have a potent and selective inhibitor of cGMP-spe-
cific PDE-5, the predominant isozyme that metabolizes
cGMP in the corpus cavernosum of the penis [6].
cGMP is the second messenger of NO and, a principal
mediator of smooth muscle relaxation and vasodilata-
tion in the penis. By inhibiting the hydrolytic break-
down of cGMP, sildenafil prolongs the action of
cGMP; this results in augmented smooth muscle
relaxation, and hence, prolongation of the erection.
Prior production of cGMP by NO released primarily
from the nonadrenergic, noncholinergic (nitroxidergic)
cavernosal nerves in response to sexual stimulation is
required for sildenafil to be effective [7]. Both erectile
dysfunction and cardiovascular disease share common
risk factors, therefore, any drug used to treat erectile
dysfunction may exert an impact upon patients with
high incidence of diagnosed or covert cardiovascular
disease. For this reason, it seems plausible to under-
stand the effects of phosphodiesterase type 5 inhibitors
and any other drugs used for the treatment of erectile
dysfunction on the cardiovascular system [8]. In a
study conducted on eleven patients with pulmonary
hypertension, it is shown that sildenafil has beneficial
effect on cerebrovascular reactivity indicated by
improvement in neurovascular coupling in these
patients [9]. In vitro, at high concentration, sildenafil
was found to dilate isolated cerebral arteries of guinea
pig; the response of vasodilatation was augmented by
sodium nitroprusside pre-treatment and attenuated by
endothelial removal or pharmacological inhibition of
endogenous cGMP production [10,11]. It was proposed
that such results support the lack of vascular response
in human in vivo studies and may suggest a possible
neural rather than vascular effect of sildenafil in
migraine induction[11]. Aim of this study was to deter-
mine whether sildenafil modulates cerebrovascular
reactivity (CVR) in patients with type 2 diabetes
mellitus.
Subjects and Methods
A total of thirty five subjects were participated in this
study after obtaining their signed consent and formal
approval of the Ethical Committee of the Faculty of
Medicine of Kufa University. They were divided into
two groups: Seventeen healthy volunteers, of a mean age
of 45 ± 2.17 years (range: 33-58) and eighteen patients
with type 2 DM, of a mean age of 50 ± 1.35 years
(range: 42-57); the mean duration of diabetes from the
time of diagnosis was 11.3 ± 6.35 years (range: 3-24).
The study started from 26/10/2008 and ended in 3/7/
2009. Patients were considered as diabetic according to
World Health Organization definition of diabetes as
fasting plasma glucose ≥ 7.0 mmol/L (126 mg/dL) or 2-
hour post-load plasma glucose ≥ 11.1 mmol/L (200 mg/
dL), according to WHO consultation, definition, diagno-
sis and classification of diabetes mellitus (1999). The
selection of diabetic patients and normal subjects was
according to certain inclusion and exclusion criteria
(table 1, 2). For all patients meeting inclusion criteria,
medical and surgical histories and demographic infor-
mation were recorded. All participants were subjected
for laboratory investigations including urine for albumin,
fasting blood sugar, serum lipid profile, blood urea, crea-
tinine, uric acid and liver function test. Full history and
neurological motor, sensory and autonomic examination
were undertaken to exclude diabetic neuropathy. For all
participants, a full physical examination including heart
rate, blood pressure measurements and a 12-lead elec-
trocardiogram, were performed.
Protocol of Transcranial Doppler examination
TCD examination was conducted in a quiet temperature
- controlled room at 9:00 am, after an overnight fast.
Siemens Versa plus Sonoline equipment (230 PAL ver-
sions, Germany) with Color flow and TCD facilities was
used for this purpose; a phase array probe of 2-2.5 MHz
was used to insonate the MCA. All subjects were
allowed to rest quietly for at least 10 minutes to achieve
as t e a d ys t a t eo fh e a r tr a t ea n db l o o dp r e s s u r e .B e f o r e
proceeding to the definitive recordings, subjects were
trained to perform the procedure of breath hold and
hyperventilation correctly. Blood pressure and heart rate
were recorded, using mercurial sphygmomanometer
ALPK2, and digital infra-red pulse-oximeter respectively.
To study the MCA blood flow velocities, the subject
was asked to tilt his head to a side and to breath normal
quiet breathing, the MCA was first identified (the proxi-
mal portion), by color flow, utilizing a trans-temporal
window. To obtain MCA spectral wave form, pulse
Table 1 Inclusion criteria
Criteria type Inclusion criteria
Patient criteria 1. Male
2. Type 2 diabetes mellitus for diabetic group
3. Co-operative
TCD examination
criteria
4. Sufficient trans-temporal window for TCD
examination.
5. Sufficient trans-orbital window for TCD
examination
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middle of the artery, at an angle of 0° and the means of
PSV, DV and RI of 10 consecutive cardiac cycles were
recorded. To demonstrate the response of MCA flow to
hypercapnea, the subject was asked to hold breath, as
long as possible, after mild to moderate deep inspiration
to avoid suffocation; the changes of mean flow velocity
of MCA to breath hold (BHmca) was calculated as the
mean of each of the above cited parameters during the
last 5 sec. To demonstrate the response of MCA to
hypocapnea, the subject was asked to perform moderate
hyperventilation for 1.5 min, Doppler spectral para-
meters of changes in MCA flow and the mean flow
velocity of MCA to hyperventilation (HVmca)w e r ec a l -
culated in the same for mentioned manner.
A 50 mg of sildenafil was then given orally; a period
of 50 minutes was allowed to elapse to ensure maximal
effect of the drug. Another Doppler waveform baseline
control of MCA was taken and all maneuvers to elicit
MCA vasoreactivity were repeated in the same fashion
cited above.
Calculation of Doppler Indices
1. Resistive index (RI) [12]
RI was calculated from the following equation
RI =

peak systolic velocity (PSV) − end diastolic velocity (EDV)

PS
2. Mean flow velocity (MFV) [13]: The mean flow
velocity baseline control of MCA (MFVmca) was calcu-
lated as[13]
MFV = (PSV + 2DV)

3
3. Breath hold index (BHI): The breath hold index
(BHI) is calculated as
BHI =

(MFVBH − MFVbaseline)

MFVbaseline

× 100

seconds of breath hold (4)
4. Full range of vasodilatation (FVD): The full range of
vasodilatation is calculated according equation Markus
& Harrison(1992)
FVD = 100 ×

Vmca

hypercapnea

− Vmca

hyperventilation

Vmca (rest)
Statistical analysis
Data were expressed as mean ± SEM. Paired t-test
was used to compare the difference between pre-
and post treatment of each group. Independent t-test
was used to compare the difference between diabetic
and normal groups. Statistical analysis was per-
formed using computer program (SPSS), version 12.
In all tests P value < 0.05 was considered to be sta-
tistically significant.
Results
In all 35 participants, there were no statistically signifi-
cant differences in the baseline demographic and bio-
chemical characteristics regarding age, body mass index
(BMI), serum triglyceride, serum VLDL and serum uric
acid (p > 0.05). Fasting serum glucose was significantly
higher in diabetic group than in normal group (p <
0.05). Serum cholesterol, LDL and atherogenic index
were significantly higher in diabetic group than in nor-
mal group (p < 0.05) while serum HDL was lower in
diabetic patients (table 3).
Effect of sildenafil on mean flow velocity (MFV) of MCA in
normal subjects and diabetic groups
Breath holding significantly increased MFV of MCA
in both normal subjects and diabetic patients before
and after giving sildenafil (p < 0.05). Hyperventila-
tion significantly decreased MFV in both normal
subjects and diabetic patients before and after silde-
nafil (p < 0.05); there was no statistically significant
change (increase or decrease) of MFV, after sildenafil
during baseline, breath hold/hyperventilation maneu-
ver, in comparison to those before sildenafil, in both
normal and diabetic groups(p > 0.05) (Table 4
F i g u r e s1 ,2 ,3 ,4a n d5 ) .
Table 2 The exclusion criteria for diabetic patients and
normal volunteers in this study
Exclusion criteria
1. Penile anatomical defect. 11. History of alcohol or drug
abuse.
2. History of priapism. 12. Hypotension (BP < 90/60
mmHg)
3. History of prostatectomy 13. Uncontrolled hypertension
(BP > 170/100)
4. History of cerebrovascular
disease transient ischaemic attack
(TIA), complete stroke or
extracranial or intracranial steno-
occlusive lesions or altered
cerebral hemodynamic.
14. Proliferative retinopathy,
retinitis pigmentosa.
5. Major hematological, renal, or
Hepatic disorder.
15. Autonomic neuropathy
6. Any major psychiatric disorder 16. History of ketoacidosis in the
previous 2 years
7. Treatment with nitrates 17. History of asthma or chronic
obstructive pulmonary disease
(COPD).
8. Coronary artery disease 18. Recent abdominal surgery.
9. History of myocardial infarction
(MI).
19. Eye disease like cataract,
glaucoma, intra-ocular lens
implantation.
10. Peptic ulcer disease. 20. Diabetic nephropathy.
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range of vasodilatation (FVD) in normal individuals and
diabetics
There was no statistically significant change in BHI and
FVD after sildenafil in normal individuals. There was a
statistically significant increase in BHI and FVD (p <
0.05) after sildenafil in diabetic patients (see table 5 and
Figures 2, 3, 4 and 5).
Effect of sildenafil on resistive index (RI) in normal and
diabetic individuals
There was statistically significant decrease in resistive
index (RI) of MCA in both normal and diabetic groups
during breath hold before and after sildenafil (p < 0.05).
During hyperventilation, RI showed statistically signifi-
cant increase in normal individuals and diabetic patients
before and after sildenafil (p < 0.05). Comparison of the
effect of sildenafil on RI between normal and diabetic
groups revealed no statistically significant change (dur-
ing baseline, breath hold and hyperventilation (table 6
and Figures 4, 5 and 5).
Discussion
In a randomized, double-blind placebo controlled study
of twenty-eight men with erectile dysfunction; Diomedi
et al [11] reported that sildenafil had no effect on cere-
bral mean blood flow velocity. However, using breath
holding index and transcranial Doppler to assess the
endothelial response to hypercapnea, they demonstrated
that a single dose of 50 mg of sildenafil produced an
improvement in cerebrovascular reserve. Though this
may reduce the concern for the use of sildenafil in
patients at risk for cerebrovascular disease, it may
increase the concern in migraine, a common adverse
effect of sildenafil. On the ground of the above cited
conflicting reports, further studies are warranted to ver-
ify whether or not sildenafil exert a modulatory effect
on cerebral vasoreactivity, bearing in mind a paucity of
reports exists on this aspect, regarding patients with
type2 DM [11]. The present investigation was aimed to
evaluated the acute modulatory effects of sildenafil on
cerebral hemodynamic. Our findings showed that 50 mg
oral sildenafil did not produce a significant increase of
mean flow velocity of MCA at rest in both normal and
diabetics. RI did not change significantly after sildenafil;
these results are in accordance with previous studies
focusing on lack of significant changes in CBF velocity
after the administration of 100 mg sildenafil [10,14]. In
the present investigation, it was demonstrated that silde-
nafil produced a significant increase in cerebrovascular
reactivity measures (BHI and FVD) in patients with type
2 diabetes mellitus without significant change in other
hemodynamic. These results are identical with those
reported by Diomedi et al [11], who found a significant
improvement in cerebrovascular reactivity after 50 mg
of sildenafil in patients with erectile dysfunction.
Accordingly, they suggested that sildenafil increased the
sensitivity of endothelial cells to hypercapnic stimuli
through activation of NO synthase. Kruuse et al [10]
found that inhibition of phosphodiesterase-5 enzyme
induced relaxation of isolated cerebral arteries, whereas
no change in cerebral blood flow was reported after
Table 3 Baseline demographic and biochemical
characteristics
Character Diabetic patients Normal group
Age (years) 50 ± 1.35 45 ± 2.17
Fasting serum glucose mg/dl 158.4 ± 10.11 87.8 ± 2.92*
Serum cholesterol mg/dl 198.7 ± 13.55 173 ± 5.67*
Serum triglyceride mg/dl 166 ± 16.8 167.4 ± 11.2
Serum HDL mg/dl 34.2 ± 2 48 ± 1.43*
Serum LDL mg/dl 130.8 ± 13.1 91.5 ± 5.20*
Serum VLDL mg/dl 33.2 ± 3.36 33.48 ± 2.23
Atherogenic index (AI) 4.78 ± 0.29 2.64 ± 0.17*
Serum uric acid mg/dl 4.51 ± 0.37 4.38 ± 0.39
BMI 26.1 ± 0.72 26.02 ± 0.78
*P < 0.05
Table 4 The effect of sildenafil on MFV (cm/sec) of MCA
Group MFV before sildenafil MFV after sildenafil
Control Breath hold Hyperven-Tilation Control Breath hold Hyperven-Tilation
Normal 44.7 ± 2.09 61.9 ± 5.02* 26 ± 1.72* 42.5 ± 2.71 55.8 ± 3.68* 24 ± 1.57*
DM 41.2 ± 3.35 53 ± 4.64* 26.9 ± 2.36* 40 ± 3.42 56.5 ± 5.02* 26.2 ± 2.39*
*P < 0.05
Figure 1 Effect of sildenafil on MFV of MCA in normal
individual and diabetic patients.
Al-Amran et al. Diabetology & Metabolic Syndrome 2012, 4:2
http://www.dmsjournal.com/content/4/1/2
Page 4 of 7non-PDE selective or PDE-5-selective inhibition [10,15].
On the other hand, other studies showed a favorable
acute and prolonged effect of sildenafil on brachial
arterial flow-mediated dilatation (an endothelial-depen-
dent dilatation) in patients with impaired endothelial
function due to type 2 diabetes and in patients with
heart failure [16,17]. This effect may be explained as
phosphodiesterase -5 inhibitors could play a role in acti-
vating endothelial NO synthase, increasing the sensitiv-
ity of endothelial cells to vasodilatory stimuli; single
dose of sildenafil can reverse chronic endothelial dys-
function [18]. In normal subjects, sildenafil did not
increase BHI neither changed MFV RI nor PI. These
results are consistent with previous studies demon-
strated that sildenafil did not improve flow-mediated
brachial artery dilatation in healthy subjects [19]. This
diversity of the effect of sildenafil on diabetic and
healthy subjects cerebral reactivity may reflect better
improvement or perhaps amelioration of endothelial
dysfunction in diabetic patients after sildenafil. A pos-
sible explanation of the current observation is furn-
ished in the following argument: Sildenafil may
decrease endothelin-1, a potent vasoconstrictor pep-
tide, (ET-1) activity which is greater in diabetics than
in healthy subjects; it was reported that blockade of
endothelin receptor (ETA), which transudes the biolo-
gical effects of ET-1, results in vasodilatation in
patients with diabetes but not in control group [20]
Moreover, Gilbert and co workers [21] found that
Endothelin-1 reduces cerebral artery sensitivity to
nitric oxide and blockade of (ETA) receptor sensitizes
vascular smooth muscle to exogenous and endothe-
lium-derived NO. More relevant data to support our
findings was provided by several studies [17] observed
that cyclic GMP decreased in those with endothelium
dysfunction due to decreased synthesis of cGMP and
increased degradation of cGMP by phosphodiesterase
or downstream abnormalities in the cGMP signal
transduction pathway. Thus, it can be said that silde-
nafil, as PDE-5 inhibitor, increases the bioavailability
of cGMP and consequently improves of endothelial
dysfunction. Fisher et al [22]; Lincoln [23] provided
evidence that sildenafil stimulates the synthesis of
inducible nitric oxide synthase (iNOS) and eNOS
mRNA in cardiac myocytes, resulting in increased NO
generation, guanylate cyclase activation and enhanced
formation of cGMP. However, there appears to be a
Figure 2 Effect of sildenafil on BHI in normal persons and
diabetic patients.
Figure 3 Effect of sildenafil on FVD of MCA in normal persons
and diabetics.
Table 5 Effect of sildenafil on BHI and FVD of MCA
Group Breath Hold Index (BHI) Full Range of Vasodilatation
(FVD)
Before
sildenafil
After
sildenafil
Before
sildenafil
After
sildenafil
Normal 0.91 ± 0.11 0.81 ± 0.09 59.4% ± 6.3% 53.7% ± 4.9%
DM 0.74 ± 0.14* 1.03 ± 0.14* 60.2% ± 4.96%
*
74% ± 4.8%*
*P < 0.05
Figure 4 Effect of sildenafil on resistive index of MCA.R I :
resistive index, C: control, N:normal persons, DM: diabetes mellitus,
BH: breath hold, HV: hyperventilation.
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vasculature endothelial dysfunction. Dishy et al [21]
c o n c l u d e dt h a ts i l d e n a f i ld i dn o tp o t e n t i a t ee n d o g e n -
ous NO-mediated vascular responses in forearm con-
duit or resistance vessels in chronic smokers. In
another study, it was concluded that sildenafil did not
improve peripheral endothelium dependent vasomotor
or fibrinolytic function in patients with coronary heart
disease; Phosphodiesterase type 5 inhibitors were unli-
kely to reverse the generalised vascular dysfunction
seen in patients with coronary heart disease [19].
Further study, with larger sample size, is therefore
recommended, to support our fore mentioned findings.
Conclusion
Sildenafil improves cerebral vasoreactivity in type 2 dia-
betic patients but not in normal individuals. In this
account, an oral administration of low dose of PDE-5 inhi-
bitors may be favored in these patients, to improve
endothelial function and hence CVR. Sildenafil has no
appreciable effect on MFV of MCA baseline mean velocity
blood flow in both normal subjects and diabetic patients.
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